Phil Kletnieks oversees analytical testing and stability across InCarda’s pipeline as well as aiding in the qualification of materials and vendors along the supply chain.
Phil has over 12 years of experience in analytical chemistry and quality control in the pharmaceutical industry across the fields of oncology, cardiovascular, hepatic, and respiratory diseases and ranging from pre-clinical to Phase 3 development. Prior to InCarda, Phil was at Eidos Therapeutics where he oversaw the analytical chemistry for a global Phase 3 program evaluating a transthyretin stabilizer to treat amyloidosis.
Prior to Eidos, he worked at Gilead Sciences for 10 years where he led the analytical chemistry teams for programs to treat NASH, atrial fibrillation, and chronic lymphocytic leukemia.
Phil earned his BS and MS in chemistry at Concordia University in Montreal, Canada and his PhD in Chemistry at the University of Southern California.